What can we learn from Biogen's decision to halt sales of aducanumab?
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Advertisement
Articles by Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Advertisement
Latest Updated Articles
Current Implications for the Managed Care of DementiaPublished: December 1st 2007 | Updated:
- The Costs of Alzheimer's Disease and the Value of Effective Therapies
Published: November 11th 2011 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads
2
New Legislation Aims to Address Transparency in PBMs as First Major Step in Reform
3
Overcoming Mistrust in Clinical Trial Enrollment Through Community Resources: Susan Vadaparampil, PhD, MPH
4
Catchment Areas Shape Diversity and Access in Oncology Trials: Amir Fathi, MD
5